Targeting PKC in Human T Cells Using Sotrastaurin (AEB071) Preserves Regulatory T Cells and Prevents IL-17 Production  by He, Xuehui et al.
Targeting PKC in Human T Cells Using Sotrastaurin
(AEB071) Preserves Regulatory T Cells and Prevents
IL-17 Production
Xuehui He1, Hans J.P.M. Koenen1,6, Ruben L. Smeets2,6, Romy Keijsers3, Esther van Rijssen1,
Andreas Koerber4, Peter C. van de Kerkhof3, Annemieke M.H. Boots5,6 and Irma Joosten1,6
Regulatory T-cells (Treg) are crucial for immune homeostasis and prevention of immune pathology. Yet, Treg may
lose Foxp3 and start secreting IL-17, dependent on environmental cues. Our previous data revealed that Treg from
severe psoriasis patients are particularly prone to such conversion. The question of how to maintain Treg stability
in the context of inflammation awaits immediate resolution. The pan-protein kinase C (PKC) inhibitor sotrastaurin
has shown efficacy in clinical trials of psoriasis. Here, we show that sotrastaurin inhibited effector T-cell
responses, whereas the regulatory response was enhanced. Sotrastaurin prevented TCR/CD28-induced T-cell
activation and pro-inflammatory cytokine production, but preserved a stable Treg phenotype as evidenced by
maintenance of suppressive capacity, high Foxp3 and CD25 expression, and lack of IL-17A and IFNg production.
Moreover, in both circulating and dermal psoriatic Treg, prone to rapid induction of IL-17, sotrastaurin enhanced
Foxp3 expression and prevented IL-17A and IFNg production even when stimulated in the presence of the helper
T 17-enhancing cytokines IL-1b or IL-23. Thus, pharmacological inhibition of PKC may serve as a powerful tool to
concurrently inhibit effector T cells and to facilitate Treg, thereby showing therapeutic potential for the treatment
of psoriasis.
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INTRODUCTION
Regulatory T cells (Treg) are crucial for maintaining immune
homeostasis. Their significance was demonstrated in a variety
of preclinical autoimmunity models and their clinical rele-
vance was proven by demonstrating that the suppressive
function of Treg was hampered in autoimmunity and allergy
(Buckner, 2010). This knowledge is currently exploited for the
development of new therapeutic designs in the management
of human chronic inflammatory diseases. However, recent
insights point to the notion that human Treg may lose the
expression of the Treg-master transcription factor Foxp3 and
convert into less suppressive and even IL-17-producing
phenotypes under pro-inflammatory environmental stimuli
(Koenen et al., 2008; Beriou et al., 2009; Voo et al., 2009).
IL-17 is considered an important mediator in psoriatic disease.
Recently, we demonstrated that Treg of psoriasis patients
revealed a remarkably high propensity to differentiate into
IL-17A-secreting cells, with enhanced loss of Foxp3 and a
higher RORyt expression (Bovenschen et al., 2011). The
concurrent presence of IL-17þ Foxp3þCD4þ Treg in
human psoriatic skin lesions led us to believe that this rela-
tive Treg instability may contribute to perpetuation of skin
inflammation. Thus, the question of how to maintain human
Treg stability under in vivo inflammatory conditions awaits
immediate resolution, and the search for pharmaceutical
agents that may realize such a feat has only just started.
Foxp3 expression is under tight epigenetic control (Huehn
et al., 2009; Lal et al., 2009) and pharmaceutical agents such
as DNA methyltransferase inhibitors and histone deacetylase
inhibitors were shown to maintain Foxp3 expression in human
Treg (Koenen et al., 2008; Polansky et al., 2008). In contrast,
many of the early T-cell activation inhibitors such as
calcineurin inhibitors have disabling effects on Treg function.
In 2008, a proof-of-concept clinical study in psoriasis
patients using the pan-protein kinase C (PKC) inhibitor
sotrastaurin (AEB071) was reported; sotrastaurin significantly
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reduced the clinical severity of psoriasis by affecting several
immune cells (Skvara et al., 2008). To date, sotrastaurin has
shown evidence of efficacy in phase II clinical trials in both
psoriasis as well as renal transplantation (Friman et al., 2011;
Wagner et al., 2011). Sotrastaurin is a low-molecular-weight
immunosuppressant that selectively targets PKC including the
PKCa, -b, and -y isoforms (Evenou et al., 2009). PKC-y, a
serine/threonine kinase belonging to the calcium-independent
PKC subfamily, is the most abundant isoform in T cells. TCR
and CD28 signaling trigger PKCy catalytic activation and
membrane translocation to the immunological synapse,
leading to activation of NFkB, activator protein-1, and
nuclear factor of activated T-cells in effector T cells. Studies
in PKC-knockout mice have shown that PKCy is required for
productive helper Th2 (Marsland et al., 2004) and Th17 (Tan
et al., 2006) responses but is dispensable for Th1 responses.
More recently, the function of PKCy in Treg has become the
focus of attention. Selective inhibition of PKCy using a
low-molecular-weight inhibitor enhanced Treg function,
suggesting that PKCy signaling negatively regulates Treg cells
via an unknown mechanism (Zanin-Zhorov et al., 2010).
Yet, most knowledge on the differential role of PKCy in
T-cell biology relies on studies in mice. Little is known about
regulation and function of PKCy in human T cells. Here, we
investigated the in vitro effects of sotrastaurin on human
effector and Treg-cell subsets. Sotrastaurin significantly inhi-
bited T-cell effector function and the production of inflamma-
tory cytokines. Importantly, sotrastaurin was found to preserve
human Treg suppressive function and prevent IL-17A produc-
tion. In Treg from psoriasis patients with impaired Treg
stability, treatment with sotrastaurin restored a bona fide Treg
phenotype and prevented Treg differentiation into inflamma-
tory effector cells. Thus, pharmacological targeting of PKC in
T cells by low-molecular-weight inhibition might be a power-
ful means to simultaneously control effector T cells and
adequate Treg function.
RESULTS
AEB071 inhibits effector function of conventional T cells, but
preserves the Treg phenotype even under pro-inflammatory
conditions
First, we established the effect of the PKC inhibitor sotrastaurin
(AEB071) on human conventional CD4þCD25 cells (con-
ventional T; Tconv) from healthy individuals. We observed a
clear dose-dependent inhibition of the proliferative capacity of
Tconv by AEB071 following anti-CD3/anti-CD28 mAb-coated
bead stimulation (Supplementary Figure S1a online). To
exclude the possibility that the observed proliferation inhibi-
tion was due to induction of cell apoptosis, cells were stained
for the active form of Caspase 3, a central mediator of
apoptosis. No obvious differences in the percentages of
Caspase 3-positive cells between untreated and treated groups
were noted (Supplementary Figure S1b online).
Then, cells were stimulated with anti-CD3/anti-CD28 mAb-
coated beads in the presence or absence of AEB071 or
rapamycin and phenotypically analyzed by flow cytometry
over a 6-day culture period. AEB071 prevented the expression
of the T-cell activation markers CD69, CD25, and HLA-DR
(Figure 1a). Expression of the negative co-stimulatory
molecules PD1 and CTLA4 during T-cell activation was also
prevented by AEB071. Activated human CD4þCD25 cells
may transiently express Foxp3, but stable expression of Foxp3
is correlated with suppressor function in Tregs (Tran et al.,
2007). In our Tconv cultures, the transient expression of Foxp3
peaked at day 3 of culture. AEB071 treatment significantly
prevented not only the increase in the number of Foxp3-
positive cells (Figure 1a) but also the expression level of Foxp3
(mean fluorescence intensity, data not shown). Foxp3 expres-
sion was low at day 6 of the culture in both the treated and
untreated conditions, implying that inhibition of PKC does not
favor the generation of induced Treg from Tconv.
Subsequently, we established that addition of AEB071 to
cultures of activated Tconv significantly inhibited the produc-
tion of IL-17A (Figure 1b) and IFNg (Supplementary Figure S1c
online) at both day 3 and 6. Addition of rapamycin also
completely inhibited IL-17A secretion.
We next assessed the effect of AEB071 on Treg from healthy
individuals. As a comparator, we included rapamycin, which
is known to harness human Treg function both in vitro and
in vivo (Tresoldi et al., 2011). AEB071 dose dependently
inhibited Treg proliferation following stimulation with
either anti-CD3/anti-CD28 mAb-coated beads or phorbol
12-myristate 13-acetate (PMA)/soluble anti-CD28 mAb in the
presence of exogenously added recombinant human
interleukin-2 (rhIL-2, Figure 2a). The IC50 of AEB071 was
0.09mM under the stimulation with CD3/CD28/rhIL-2 and
0.15mM when PMA/CD28/rhIL-2, a PKC-skewing activation
method, was used (Smeets et al., 2012). Rapamycin was less
potent in the inhibition of Treg proliferation as compared with
Tconv, 30% (Treg, Figure 2a) vs. 70% (Tconv, Supplementary
Figure S1a online). Higher concentrations of rapamycin did
not result in further inhibition of Treg proliferation. Further,
AEB071-treated Treg did not show increased apoptosis
(Supplementary Figure S1d online), indicating that the com-
pound does not affect Treg-cell viability by apoptosis induc-
tion. Rapamycin treatment also did not affect Treg apoptosis
induction.
To evaluate the impact of PKC inhibition on Treg pheno-
type, the expression of Foxp3 and CD25 was analyzed upon
stimulation with CD3/CD28/rhIL-2 or PMA/CD28/rhIL-2.
For comparison and confirmation purposes, we used the
selective PKCy inhibitor C20. Similar to rapamycin, inhi-
bition of PKC using either AEB071 or C20 largely preserved
the expression of Foxp3 and CD25 (both percentage and mean
fluorescence intensity) regardless of the stimulation protocol
(Figure 2b). Notably, the administration of rapamycin signifi-
cantly enhanced the mean fluorescence intensity of CD25.
Recent studies provided evidence for functional hetero-
geneity and lineage plasticity within the Treg compartment.
Under certain conditions, Treg may acquire an effector
phenotype including the ability to produce IFNg and/or
IL-17A. Here, we measured the amount of IFNg and IL-17A
produced by Treg after treatment with AEB071, C20, or
rapamycin. In the absence of any inhibitors, Treg did produce
somewhat IFNg upon stimulation. Interestingly, AEB071
almost completely blocked this IFNg production (Figure 2c).
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A similar inhibition was seen in the presence of rapamycin
or C20. In line with several reports (Koenen et al., 2008;
Voo et al., 2009), IL-17A was produced by Treg stimulated
with CD3/CD28/rhIL-2, and its production was enhanced
by the pro-inflammatory cytokine IL-1b (Figure 2d). In con-
trast, IL-17A was hardly detected following treatment with
AEB071, C20, or rapamycin. Importantly, AEB071, similar
to rapamycin, successfully prevented Treg from producing
IL-17A, even in the presence of IL-b (Figure 2d). It has been
suggested that the ratio of Foxp3/RORgt determines the Treg/
Th17 plasticity (Bettelli et al., 2006). However, we were
unable to find any significant change of Foxp3 (Figure 2b)
and RORgt (Figure 2e) expression in our set up.
To explore the effect of PKC inhibition on Treg suppressor
function, Treg were stimulated with anti-CD3/anti-CD28/rhIL-
2 for a week in the presence/absence of AEB071, rapamycin,
or C20. Thereafter, viable expanded Treg were co-cultured
with carboxyfluorescein diacetate succinimidyl ester (CFSE)-
labeled CD4þCD25 responder T cells (Tresp) at different
ratio’s of Treg:Tresp, and the dilution of CFSE was determined
after 3 days of culture. According to expectation (Coenen
et al., 2006; Tresoldi et al., 2011), Treg expanded in the
presence of rapamycin demonstrated preserved suppressor
function when compared with the untreated condition
(Figure 3a and b). Interestingly, treatment with AEB071 proved
just as successful in maintaining suppressor function (Figure 3a
and b), similar to C20 treatment (Figure 3c). At a ratio of 1:1
(Treg:Tresp), the proliferation of Tresp was inhibited 480%
under all conditions tested, including Treg treated with
AEB071. At a ratio of 1:2 (Treg:Tresp), still over 50% inhibition
of Tresp proliferation was observed in the AEB071-treated
condition.
AEB071 preserves phenotype and function of circulating Treg
from psoriasis patients
Previously, we showed that, as compared with healthy
controls, Treg from psoriasis patients upon stimulation exhibit
enhanced loss of Foxp3, the master transcription factor
associated with suppressor function, and increased production
of IL-17A (Bovenschen et al., 2011). This was particularly so
when stimulated in the presence of IL-23 or IL-1b. Therefore,
having established that in healthy Treg AEB071 preserves Treg
function and phenotype, we explored whether AEB071 may
improve Treg function in psoriasis patients. We isolated either
CD4þ lymphocytes or CD4þCD25high Treg from patient
peripheral blood mononuclear cells, and stimulated the cells
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Figure 1. AEB071 inhibits conventional T (Tconv)-cell activation and IFNc/IL-17A production. CD4þCD25 Tconv were stimulated with anti-CD3/anti-CD28
mAb-coated beads with or without AEB071 (10mM) or rapamycin (200 nM) and phenotypically analyzed at day 1, 3, or 6. (a) Representative dot-plots showing
CD69, HLA-DR, CD25, PD1, CTLA4, and Foxp3 expression at day 6 of culture (left panel) and cumulative data showing the frequency of each marker
analyzed (right panel), n¼ 6. (b) Presence of IL-17A in cell culture supernatants at days 3 and 6 as measured by Luminex. Each data point represents a
separate experiment performed with CD4þCD25 cells obtained from different healthy blood donors, n¼ 6. *Po0.05; **Po0.01, ***Po0.001.
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with anti-CD3/anti-CD28 mAb-coated beads plus rhIL-2 in the
presence/absence of AEB071 or rapamycin for a week. Th17
polarizing cytokines IL-1b or IL-23 were also administrated to
the cell culture. In the total psoriatic CD4þ T-cell pool, the
addition of AEB071 or rapamycin resulted in enhanced
Foxp3þ cell numbers as compared with the standard
stimulation, especially in the presence of IL-23 (Figure 4a).
More importantly, under these conditions, AEB071 signifi-
cantly inhibited both IL-17A and IFNg production (Figure 4b).
Then, we analyzed FACS-sorted Treg from patient peripheral
blood. Confirming our previous results (Bovenschen et al.,
2011), these cells showed a markedly diminished expression
of Foxp3 following stimulation, which was enhanced by the
addition of IL-1b or IL-23 (Figure 4c, upper part left panel).
Whereas in healthy Treg, AEB071 treatment maintained a
similar level of Foxp3þ cells (Figure 2) as compared with the
untreated condition, in patient Treg, treatment with AEB071 or
rapamycin not only prevented the loss of Foxp3, but slightly
enhanced it, even in the presence of IL-1b or IL-23 (Figure 4c).
Moreover, this feature was accompanied by a reduced
production of IL-17A (Figure 4d).
AEB071 prevents IL-17A and IFNc production by skin-resident
T cells
Recruitment of T cells into the skin and their effector responses
are considered to be key features in the pathogenesis of
psoriasis. We therefore investigated the effect of AEB071 on
skin-resident T cells. Single dermal cell populations were
prepared from skin biopsies from lesional skin of psoriasis
patients (n¼5) or skin from healthy individuals (n¼ 3).
Figure 5a shows the percentage of cutaneous lymphocyte
antigen and Foxp3-positive cells in the CD3þ population
thus obtained (Figure 5a). Culture strategies are outlined in
Figure 5b. First, we stimulated freshly isolated primary dermal
T cells with anti-CD3/anti-CD28 mAb-coated beads plus rhIL-
2 and IL-1b for 12 days, in the presence or absence of
AEB071. Similar to its effect on blood-derived circulating T
cells (Supplementary Figure S1a online), and as compared
with the nontreated condition, AEB071 strongly inhibited
proliferation of primary dermal T cells in both samples from
psoriasis patients and those from healthy controls (data not
shown). As very few dermal T cells proliferated in the
presence of AEB071, hampering more extensive analysis, we
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Figure 2. AEB071 preserves regulatory T cell (Treg) phenotype and prevents Treg from producing IFNc/IL-17A. FACS-sorted CD4þCD25high Treg were
stimulated with anti-CD3/anti-CD28 mAb-coated beads or phorbol 12-myristate 13-acetate (PMA)/anti-CD28 mAb plus recombinant human interleukin-2 (rhIL-2)
in the presence of a graded dose of AEB071 (red line) or rapamycin (blue line). (a) Proliferation of Treg was measured by [3H]-thymidine incorporation during
the last 6 hours of a 7-day culture, n¼ 5. (b) Flow cytometry of Treg cultured for 7 days as described above in the presence of AEB071 (1mM), rapamycin (200 nM),
or C20 (1mM). Representative dot-plot showing CD25þ Foxp3þ expression (left panel) and cumulative data showing the frequency and mean fluorescence
intensity (MFI) of CD25þ and Foxp3þ cells (right panel), n¼3. (c, d) Presence of IFNg and/or IL-17A in cell culture supernatant at day 7 as measured by
Luminex. IL-1b was added to the culture where indicated. (e) Cumulative data showing the frequency of RORgtþ cells. All experiments were performed with Treg
obtained from different healthy blood donors. Meanþ SEM are shown, n¼3. NS, not significant; *Po0.05; **Po0.01.
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employed an alternative strategy to investigate the effect of
AEB071 on dermal T cells. First, we expanded primary dermal
T cells with anti-CD3/anti-CD28/rhIL-2 for 12 days. There-
after, expanded dermal T cells were collected and rechal-
lenged in the presence/absence of AEB071 for another 7 days
before performing the phenotypic analysis. Consistent with
our observation in circulating Treg, AEB071 enhanced Foxp3
expression in dermal T cells derived from both healthy
individuals and patients (Figure 5c). In addition, patient-
derived dermal T cells (primary and expanded) showed
enhanced capacity to lose Foxp3 expression upon stimulation,
which was largely prevented by treatment with AEB071
(Figure 5c). Again, similar to circulating Treg, upon stimula-
tion, psoriasis patient-derived dermal T cells produced more
IL-17A than those from healthy individuals. Also, AEB071
clearly diminished the percentage of IL-17A- as well as IFNg-
producing cells in patients (Figure 5d).
DISCUSSION
IL-17 is an important mediator in the pathogenesis of psoriasis.
Previously, we reported that Treg of psoriasis patients have
an enhanced propensity to convert into an inflammatory
phenotype and start producing IL-17 (Bovenschen et al.,
2011). We also found evidence for these IL-17-producing
Treg in psoriatic plaques. Recently, the importance of defining
agents that can prevent this type of conversion was highlighted
in view of improved therapeutic regimens for the management
of (auto)inflammatory processes (Soler and McCormick,
2011). We here hypothesized that the pan-PKC inhibitor
sotrastaurin (AEB071), now used in clinical trials to diminish
clinical symptoms in psoriasis patients (Skvara et al., 2008),
might be such an agent. Indeed, our study provides evidence
that sotrastaurin preserves the stability of human Treg; in vitro
treatment with sotrastaurin prevented circulating Treg of both
psoriasis patients and healthy controls from producing IFNg
and IL-17A, even in the presence of the IL-17-driving cytokine
IL-1b. In addition, Treg that were cultured in the presence
of sotrastaurin, similar to rapamycin, efficiently suppressed
the proliferation of responder T cells, indicating that both
compounds favor the maintenance of suppressor function.
Moreover, also in dermal T cells from lesional skin sotrastaurin
preserved Foxp3 expression and inhibited IL-17A and IFNg
production upon stimulation, features that may contribute to
the clinical effects observed upon treatment.
On the basis of data obtained in PKCy-knockout mice,
contrasting roles for PKCy in the development and function of
thymus-derived Treg were reported: while Treg numbers were
reduced, Treg suppressor function proved intact (Gupta et al.,
2008). The recent finding that the PKCy-specific inhibitor C20
increases the suppressor activity of human Treg (Zanin-Zhorov
et al., 2010) is in line with our findings, and suggests that
therapeutic strategies designed to inhibit PKC in T cells may
hold promise for the treatment of autoimmune conditions.
Sotrastaurin is a low-molecular-weight immunosuppressant
selectively targeting PKC (Evenou et al., 2009). In patients
with moderate-to-severe psoriasis, sotrastaurin resulted in a
mean reduction up to 69% for the psoriasis area and severity
index score compared with baseline after 2 weeks of treatment
(Skvara et al., 2008), suggesting the efficacy of sotrastaurin
in T cell-mediated diseases. Indeed, sotrastaurin markedly
prolonged graft survival times in experimental heart and
kidney allotransplantation animal models (Weckbecker
et al., 2010; Bigaud et al., 2012). Although a phase II
clinical trial using sotrastaurin plus MPA in renal transplant
recipients was associated with increased rejection from week
4 onward, this calcineurin inhibitor-free regimen showed an
acceptable safety profile and improved renal function (Friman
et al., 2011), which support further study of sotrastaurin as a
component of multidrug immunosuppressive regimens.
Several studies revealed that under pro-inflammatory envir-
onmental stimuli, human Treg may lose Foxp3 and convert
into less suppressive and even inflammatory phenotypes
(Koenen et al., 2008; Beriou et al., 2009; Voo et al., 2009).
Here, we showed that sotrastaurin maintained the regulatory
phenotype of Treg as characterized by the expression of
Foxp3 and CD25 and preserved suppressor function. More
Treg:Tresp = 1:1 Treg:Tresp = 1:2
Treg:Tresp = 1:1 Treg:Tresp = 1:2
Tre
sp
+ 
Tre
g_M
ed
ium
+ 
Tre
g_A
EB
07
1
+ 
Tre
g_R
ap
am
yci
n 
Tre
sp
+ 
Tre
g_M
ed
ium
+ 
Tre
g_A
EB
07
1
+ 
Tre
g_R
ap
am
yci
n 
0
25
50
75
100
NS
%
 In
hi
bi
tio
n 
of
 T
re
sp
ce
ll 
pr
ol
ife
ra
tio
n 
0
25
50
75
100
NS
CFSE
Ev
en
t
Treg:Tresp = 1:2
Tresp
+ Treg_Medium
+ Treg_C20
+ Treg_Rapamycin
Tresp
+ Treg_Medium
+ Treg_AEB071
+ Treg_Rapamycin
CFSE
Ev
en
t
Figure 3. Inhibition of protein kinase C (PKC) preserves regulatory T cell
(Treg) suppressive function. Carboxyfluorescein diacetate succinimidyl ester
(CFSE)-based co-culture suppression assay of CD4þCD25high Treg that were
stimulated with anti-CD3/anti-CD28/rhIL-2 in the absence or presence of
AEB071 (1mM), C20(1mM), or rapamycin (200 nM). (a, c) A representative
overlay histogram of CFSE-based suppression assay is shown on day 3 of co-
culture. (b) Cumulative data showing %inhibition of Tresp proliferation
induced by expanded Treg that were cultured according to the conditions
mentioned. All experiments were performed with CD4þCD25high and
CD4þCD25 cells obtained from different healthy blood donors, n¼ 5
(a, b) or n¼ 3 (c). Meanþ SEM are shown. NS, not significant; Tresp, responder
T cells.
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importantly, upon stimulation of Treg, sotrastaurin, similar to
rapamycin (Yurchenko et al., 2012), not only preserved
expression of Foxp3 and CD25 but also prevented Treg from
producing IL-17A. The stabilizing effect of sotrastaurin was
found in Treg from healthy individuals as well as from those of
psoriasis patients, even in the presence of the Th17-enhancing
cytokines IL-1b or IL-23. As psoriatic Treg are far more prone
to convert into IL-17 producers and being in an inflammatory
environment, this stabilizing feature is of particular relevance
in the treatment of psoriasis patients.
The mechanism by which PKC affects Treg fate and function
is largely unclear. In effector T cells, PKCy is recruited to the
immune synapse with the specific purpose of destabilizing the
connection and possibly allowing for subsequent antigen
encounter, thereby favoring Th2 and Th17 development
(Yokosuka et al., 2008). In contrast, mouse studies revealed
that in Treg, the PKC/CARMA/NFkB complex was found
localized outside the immune synapse (Zanin-Zhorov et al.,
2011). This implies that inhibition of PKC-mediated activation
of NFkB/Ap1 is beneficial during Treg activation, whereas
inhibition of the NFkB/Ap1-mediated inflammatory pathway is
detrimental for (Th2 and Th17) effector function. The fact that
rapamycin is able to stabilize Treg suggests that multiple
pathways are likely involved. Treg stability through rapamycin-
mediated inhibition of mammalian target of rapamycin may
be achieved in a direct way through inhibition of protein
synthesis or indirectly by modulating cellular metabolism
via protein kinase B (PKB/Akt). This is underlined by the
phenomenon that effector T cells and Treg require distinct
metabolic programs to support their functions; Th1, Th2, and
Th17 cells are highly glycolytic, whereas Treg have high lipid
oxidation rates in vitro (Michalek et al., 2011). Importantly,
hypoxia-inducible factor-1, a key metabolic sensor, was
shown to control the balance between the reciprocally regu-
lated Th17 and Foxp3þ Treg cell lineage, which appeared to
be dependent on mammalian target of rapamycin (Dang et al.,
2011; Shi et al., 2011). Thus, the data imply that pharmaco-
logical inhibition targeting either PKC or mammalian target of
rapamycin (by sotrastaurin and rapamycin, respectively) may
be used to control Treg- and Tconv-specific functions in
inflammatory disease.
Further, we found that different IC50s of sotrastaurin were
obtained for Tconv and Treg subsets, and under different
stimulation conditions (e.g., CD3/CD28 and PMA/CD28).
Some of this can be explained by our previous finding that
PMA/CD28-induced T-cell stimulation is highly dependent on
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Figure 4. AEB071 prevents the extensive loss of Foxp3 and inhibits IFNc/IL-17A production by peripheral regulatory T cells (Treg) from psoriasis patients.
CD4þ T cells or CD4þCD25high Treg isolated from psoriasis peripheral blood were stimulated with anti-CD3/anti-CD28 mAb-coated beads in the
absence/presence of AEB071 (1mM) or rapamycin (200 nM) for 7 days. IL-1b or IL-23 was included where indicated. In case of Treg, rhIL-2 was also administrated
to the cultures. (a) Cumulative data showing the frequency of Foxp3þ cells as measured by flow cytometry, n¼11. (b) Cumulative data showing the
amount of IFNg and IL-17A in the culture supernatants of patient CD4þ cells as measured by Luminex, n¼ 11. (c) Representative dot-plots showing Foxp3
expression on Treg from two different psoriatic patients following stimulation as described above for 7 days. Cumulative data showing the frequency of Foxp3þ
cells (right panel), n¼ 7. (d) Cumulative data showing the amount of IL-17A in psoriatic patient Treg-cell culture supernatants at day 7 of culture. Each data point
represents a separate experiment, performed with cells isolated from a different psoriasis patient, n¼7. *Po0.05; **Po0.01; ***Po0.001. PAT, patient.
X He et al.
Sotrastaurin Preserves Treg in Psoriasis
980 Journal of Investigative Dermatology (2014), Volume 134
the PKCy pathway, whereas CD3-mediated pathways are
dependent on both Lck and PKCy signal transduction
(Smeets et al., 2012). Although sotrastaurin dose depen-
dently inhibited both Tconv- and Treg-cell proliferation, the
IC50 for Treg was always lower than that for Tconv regardless
of the stimulus provided. This may be explained by the
following: (1) differences in expression of environmental
sensors and ensuing signal transduction pathways involved
in Treg and Tconv subsets; (2) differences in PKCy cellular
concentrations and cellular localization as reported recently
for Treg and Tconv. Higher sensitivity of Treg to PKC
inhibition may be favorable for preventing Treg reprogram-
ing in vivo. More studies are needed to establish optimal
dosing of PKC inhibitors for stabilizing Treg function while
maintaining T-cell homeostasis.
In conclusion, here, we showed that sotrastaurin inhibited
effector T-cell responses, whereas the regulatory response was
enhanced, a feature observed even in the presence of IL-1b. In
addition, we provide evidence for the role of PKC in the
balance of Treg and Th17 differentiation and show that this
mechanism also holds true for both circulating and skin-
derived T cells from psoriasis patients. Inhibition of PKC thus
appears to control Treg fate by preventing Treg differentiation
into inflammatory effector T cells. Pharmacological inhibition
of PKC may thus add to strategies for Treg facilitation in the
treatment of autoimmune-related disorders, such as psoriasis.
MATERIALS AND METHODS
Cell isolation and culture
Buffy coats were obtained from healthy blood donors (Sanquin Blood
Bank, Region South-East, The Netherlands) upon written informed
consent, according to the Declaration of Helsinki Principles. In total,
16 psoriasis patients were recruited to this study and peripheral blood
was collected by vena puncture. The average psoriasis area and
severity index score was 10.3±2.5 (mean±SEM). Patients were
either untreated (n¼ 5) or treated with methotrexate (n¼ 7), fumaric
acid (n¼ 3), or UVB (n¼ 1). This study was carried out in Radboud
University Medical Centre in accordance with the applicable rules
concerning the review of research ethics committees and upon
written informed consent. Peripheral blood mononuclear cells
and CD4þ were isolated and cultured as described previously
(He et al., 2011). Briefly, the resultant CD4þ fraction was labeled
with anti-CD25-PE (M-A251; BD Biosciences, Erembodegem,
Belgium) and anti-CD4-PC5 (13B8.2, Beckman-Coulter, Mijdrecht,
The Netherlands), conjugated mAbs; thereafter, Tconv (CD4þ
CD25 ) and Treg (CD4þCD25high) were sorted using an Altra or
Aria cell-sorter (Beckman-Coulter). Cell purity was over 98%.
CD4þCD25 Tconv were stimulated with anti-CD3/anti-CD28
mAb-coated beads (T Cell Expanders, Dynal Biotech, Oslo, Norway)
in a bead:cell ratio of 1:5, in the absence/presence of the indicated
concentrations of inhibitors for 4 days. CD4þCD25high Treg were
stimulated with either anti-CD3/anti-CD28 mAb-coated beads, in a
bead:cell ratio of 1:2, and recombinant human cytokines IL-2 (rhIL-2,
Un
tre
ate
d
AE
B0
71
0
20
40
60
%
Fo
xp
3+
 c
el
ls
Un
tre
ate
d
AE
B0
71
Un
tre
ate
d
AE
B0
71
Un
tre
ate
d
AE
B0
71
Un
tre
ate
d
AE
B0
71
Un
tre
ate
d
AE
B0
71
0
20
40
60
80
%
IL
-1
7+
 c
el
ls
*
Healthy Healthy
0.06
%
IF
Nγ
+
 c
e
lls
Healthy
0
20
40
60
%
Fo
xp
3+
 c
el
ls
0
20
40
60
80
%
IL
-1
7+
 c
el
ls
0
25
50
75
100
0
25
50
75
100
0.08
%
IF
N
γ+
 c
e
lls
CL
A
Foxp3
Healthy
Day 0
a
c d
b
Primary
(Day 12)
Expanded
(Day 19)
Primary
(Day 12)
Expanded
(Day 19) 
Punch skin biopsies
Single dermal cell
populations
CD3/CD28/IL-2/IL1β
+/–AEB071
CD3/CD28/IL-2
FACS CD3/CD28/IL-2/IL1β
+/–AEB071
FACS
FACSDay 0
Day 12
Day 19
Patient
Patient Patient Patient
Figure 5. AEB071 prevents IL-17A and IFNc production by skin-resident T cells. Punch skin biopsies obtained from healthy individuals and psoriasis
patients were used for preparation of the single dermal cell populations as described in Material and Methods. Thereafter, cells were either analyzed by FACS
analysis for CD3, cutaneous lymphocyte antigen (CLA), and Foxp3 expression or cultured as schematically indicated (b) with or without AEB071 (10mM).
(a) Dot-plots showing the expression of CLA and Foxp3 based on the CD3þ -gated derma cell population at day 0. Dot-plots show one representative
healthy donor and one merged dot-plot of three patients. (c) Cumulative data showing the percentage of Foxp3þ cells after the first round of 12-day stimulation
(primary (D12)) or after the second round of 7-day stimulation (expanded (D19)). (d) Cumulative data showing the percentage of IL-17A and IFNg-positive
cells at days 12 and 19 of culture. In total, three healthy and five patient skin biopsies were used.
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25 U ml 1, Proleukine, Amsterdam, The Netherlands), or PMA
(12.5 ng ml 1), soluble CD28 mAb (1mg ml 1) and rhIL-2
(25 U ml 1) in the absence/presence of the indicated concentrations
of inhibitors for a week. IL-1b (50 ng ml 1) or IL-23 (50 ng ml 1) was
added into cell cultures where described.
Cell isolation from skin
Skin punch biopsies from healthy individuals were obtained from
abdominal skin leftover of healthy individuals undergoing elective
plastic surgery at the Radboud University Medical Centre
Department of Plastic Surgery after oral or written informed consent
for scientific use. Skin punch biopsies from psoriasis patients (psoriasis
area and severity index score, 15.8±1.7, n¼ 5) were obtained from
lesional skin at the University of Essen Department of Dermatology
after oral or written informed consent for scientific use. The use of
human skin was approved and in accordance with the regulations
set by the Medical Ethical Committees for human research of the
Radboud University Medical Centre.
Biopsies (4 mm) were incubated in a 24-well plate in which each
well contains 32 mg ml 1 Dispase II (Roche, Woerden, The Nether-
lands) at 4 1C overnight for peeling-off of the epidermis. Thereafter,
biopsies were mechanically dissociated using gentalMACS tubes
(Miltenyi Biotec, Leiden, The Netherlands) followed by the incubation
with collagenase I (10,000 U ml 1, Sigma-Aldrich, Zwijndrecht, The
Netherlands) for 1 h. After the addition of DNase I (5 MU ml 1,
Calbiochem, Amsterdam, The Netherlands) and one more cycle of
mechanical dissociation, samples were filtered through a cell strainer
to obtain the single dermal cell population, referred to as primary
dermal T cells in this manuscript.
Primary dermal T cells were cultured with anti-CD3/anti-CD28
mAb-coated beads together with rhIL-2 for 12 days before either
directly performing the phenotypic analysis or used as expanded
dermal T cells for further analysis. At day 12, the expanded dermal
T cells were collected and restimulated for another 7 days before
phenotypic analysis. IL-1b (50 ng ml 1) and AEB071 (10 uM) were
added where indicated.
Inhibitory compounds
AEB071 and C20 were kindly provided by Organon NV (now Merk
Research Laboratories, MSD, Oss, The Netherlands) and Boehringer
Ingelheim Pharmaceuticals (Ridgefield, CT), respectively. Rapamycin
was purchased from Sigma. Cells were pretreated with indicated
concentrations of the inhibitors or vehicle control for 30 min at 37 1C.
Thereafter, stimulators as indicated were added to the culture
mixture.
Cell proliferation assay
Typically, 5 104 Tconv or 2 104 Treg per well were stimulated in
the presence of graded doses of inhibitors. Cell proliferation was
monitored by [3H]-thymidine incorporation using a Gas Scintillation
Counter (Canberra Packard, Matrix 96 Beta-counter, Meriden, CT) at
day 4 (Tconv) or 7 (Treg). Percentage of cell proliferation inhibition
was normalized to the control. The sigmoid curve was generated
using GraphPad Prism5.0 (San Diego, CA).
Antibodies and CFSE labeling
Cells were phenotypically analyzed by multi-colors flow cytometry
(Beckman-Coulter), using the following: anti-CD3-PeCy5 (UCHT1),
anti-CD4-PeCy5 (T4), anti-CD8-ECD (SFCI21Thy2D3), anti-CD69-
ECD (TP1.55.3), and anti-CD62L-ECD (DREG56; all from
Beckman-Coulter), anti-CD25-PeCy7 (BC96; eBioscience, Uithoorn,
The Netherlands), anti-HLA-DR-FITC (L243), and anti-PD1-FITC
(MIH4; both from BD Bioscience) mAbs. Anti-Foxp3-FITC or
-eFluo450 (PCH101), anti-RORgt-PE or -APC (AFKJS-9; both from
eBioscience), and anti-CTLA4-APC (BNI3, BD Bioscience) were
used after Fix-Perm-treatment (eBioscience). Appropriate isotype
mAbs were used to define marker settings. Fixable viability dye
(eBioscience) was used in some experiments. Data were analyzed
using the Kaluza software (Beckman-Coulter).
Cells (5 106 cells ml 1) were labeled with 0.5mM CFSE
(Molecular Probes, Leiden, The Netherlands) to monitor cell division
(Koenen et al., 2005).
Co-culture suppression assays
The suppressor capacity of expanded Treg was studied in co-culture
assays. Tregs were expanded in the absence/presence of inhibitors for
a week. Thereafter, viable Tregs were collected, washed, and added
at different ratios to CFSE-labeled CD4þCD25 responder T cells
(Tresp) together with anti-CD3/anti-CD28 mAb-coated beads for
3 days. Proliferation of Tresp was determined by analyzing CFSE
dilution as described previously (Koenen et al., 2005).
Cytokine production
IL-17A and IFNg were determined in the culture supernatants using
Luminex cytokine assays (Invitrogen, Veenendaal, The Netherlands),
according to the manufacturer’s instructions. The lower level of detec-
tion of IFNg was o5 pg ml 1 and that of IL-17A was o10 pg ml 1.
Statistics
Results are presented as mean±SEM. P-values were determined by
paired t-test or one-way analysis of variance, using the GraphPad
Prism5.0 software. P-valueso0.05 were considered statistically
significant.
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